847. Future Hepatitis Activation and Hepatocarcinogenesis in HBeAg-Negative HBV rs with Persistently Normal Alanine Aminotransferase, a Prospective Cohort Study

[Guest guest]

http://www.hbvadvocate.org/news/reports/HBV_AASLD_2008/Abstracts/Nov2%20Disease%\

20Progression.htm#Nov2a847

847. Future Hepatitis Activation and Hepatocarcinogenesis in HBeAg-Negative HBV

rs with Persistently Normal Alanine Aminotransferase, a Prospective Cohort

Study

T. Nakazawa; Y. Shibata; A. Takeuchi; Y. Okuwaki; K. Ono; Y. Miura; H. Hidaka;

Y. Tanaka; J. Takada; M. Watanabe; A. Shibuya

Background/Aims:

To elucidate the incidence of future hepatitis activation and

hepatocarcinogenesis in HBeAg-negative HBV carriers with persistently normal

alanine aminotransferase (PNALT), long-term observation was performed in a

prospective cohort.

Methods:

Ninety-nine consecutive untreated HBeAg-negative carriers with PNALT (40IU/L)

were prospectively included in the study. The physical examinations, laboratory

tests, and abdominal ultrasound sonography were performed every 6 months after

the enrollment. The incidence of hepatitis activation (ALT levels of more than

1.5x upper limit of normal) and hepatocarcinogenesis were examined. In addition,

we statistically investigated the contributed factors for hepatitis activation

and hepatocarcinogenesis among baseline clinical and virological features at the

enrollment. ALT level was classified into two groups of low-normal ALT (30IU/L)

and high-normal ALT (30-40IU/L).

Results:

The mean follow-up period was 65.3±36.8 months. Thirteen carriers (13%) revealed

hepatitis activation, and hepatocarcinogenesis was observed in 4 (3.7%). The

cumulative rate of hepatitis activation was 10.5% and 14.9% at 2 and 5 years,

while the cumulative rate of hepatocarcinogenesis was 2.9% and 12.3% at 5 and 8

years. In statistical analyses for future hepatitis activation, the univariate

analyses revealed high-normal ALT and serum HBV DNA level 105 (copies/ml), and

high-normal ALT was an independent contributed factor in a model [odds

ratio, 13.45; 95% confidence interval, 4.34-41.64, P50 years), high-normal ALT,

the incidence of hepatitis activation, and serum HBV DNA level 105 (copies/ml)

(P = 0.0045, 0.0017,

[Guest guest]

http://www.hbvadvocate.org/news/reports/HBV_AASLD_2008/Abstracts/Nov2%20Disease%\

20Progression.htm#Nov2a847

847. Future Hepatitis Activation and Hepatocarcinogenesis in HBeAg-Negative HBV

rs with Persistently Normal Alanine Aminotransferase, a Prospective Cohort

Study

T. Nakazawa; Y. Shibata; A. Takeuchi; Y. Okuwaki; K. Ono; Y. Miura; H. Hidaka;

Y. Tanaka; J. Takada; M. Watanabe; A. Shibuya

Background/Aims:

To elucidate the incidence of future hepatitis activation and

hepatocarcinogenesis in HBeAg-negative HBV carriers with persistently normal

alanine aminotransferase (PNALT), long-term observation was performed in a

prospective cohort.

Methods:

Ninety-nine consecutive untreated HBeAg-negative carriers with PNALT (40IU/L)

were prospectively included in the study. The physical examinations, laboratory

tests, and abdominal ultrasound sonography were performed every 6 months after

the enrollment. The incidence of hepatitis activation (ALT levels of more than

1.5x upper limit of normal) and hepatocarcinogenesis were examined. In addition,

we statistically investigated the contributed factors for hepatitis activation

and hepatocarcinogenesis among baseline clinical and virological features at the

enrollment. ALT level was classified into two groups of low-normal ALT (30IU/L)

and high-normal ALT (30-40IU/L).

Results:

The mean follow-up period was 65.3±36.8 months. Thirteen carriers (13%) revealed

hepatitis activation, and hepatocarcinogenesis was observed in 4 (3.7%). The

cumulative rate of hepatitis activation was 10.5% and 14.9% at 2 and 5 years,

while the cumulative rate of hepatocarcinogenesis was 2.9% and 12.3% at 5 and 8

years. In statistical analyses for future hepatitis activation, the univariate

analyses revealed high-normal ALT and serum HBV DNA level 105 (copies/ml), and

high-normal ALT was an independent contributed factor in a model [odds

ratio, 13.45; 95% confidence interval, 4.34-41.64, P50 years), high-normal ALT,

the incidence of hepatitis activation, and serum HBV DNA level 105 (copies/ml)

(P = 0.0045, 0.0017,

[Guest guest]

http://www.hbvadvocate.org/news/reports/HBV_AASLD_2008/Abstracts/Nov2%20Disease%\

20Progression.htm#Nov2a847

847. Future Hepatitis Activation and Hepatocarcinogenesis in HBeAg-Negative HBV

rs with Persistently Normal Alanine Aminotransferase, a Prospective Cohort

Study

T. Nakazawa; Y. Shibata; A. Takeuchi; Y. Okuwaki; K. Ono; Y. Miura; H. Hidaka;

Y. Tanaka; J. Takada; M. Watanabe; A. Shibuya

Background/Aims:

To elucidate the incidence of future hepatitis activation and

hepatocarcinogenesis in HBeAg-negative HBV carriers with persistently normal

alanine aminotransferase (PNALT), long-term observation was performed in a

prospective cohort.

Methods:

Ninety-nine consecutive untreated HBeAg-negative carriers with PNALT (40IU/L)

were prospectively included in the study. The physical examinations, laboratory

tests, and abdominal ultrasound sonography were performed every 6 months after

the enrollment. The incidence of hepatitis activation (ALT levels of more than

1.5x upper limit of normal) and hepatocarcinogenesis were examined. In addition,

we statistically investigated the contributed factors for hepatitis activation

and hepatocarcinogenesis among baseline clinical and virological features at the

enrollment. ALT level was classified into two groups of low-normal ALT (30IU/L)

and high-normal ALT (30-40IU/L).

Results:

The mean follow-up period was 65.3±36.8 months. Thirteen carriers (13%) revealed

hepatitis activation, and hepatocarcinogenesis was observed in 4 (3.7%). The

cumulative rate of hepatitis activation was 10.5% and 14.9% at 2 and 5 years,

while the cumulative rate of hepatocarcinogenesis was 2.9% and 12.3% at 5 and 8

years. In statistical analyses for future hepatitis activation, the univariate

analyses revealed high-normal ALT and serum HBV DNA level 105 (copies/ml), and

high-normal ALT was an independent contributed factor in a model [odds

ratio, 13.45; 95% confidence interval, 4.34-41.64, P50 years), high-normal ALT,

the incidence of hepatitis activation, and serum HBV DNA level 105 (copies/ml)

(P = 0.0045, 0.0017,

[Guest guest]

http://www.hbvadvocate.org/news/reports/HBV_AASLD_2008/Abstracts/Nov2%20Disease%\

20Progression.htm#Nov2a847

847. Future Hepatitis Activation and Hepatocarcinogenesis in HBeAg-Negative HBV

rs with Persistently Normal Alanine Aminotransferase, a Prospective Cohort

Study

T. Nakazawa; Y. Shibata; A. Takeuchi; Y. Okuwaki; K. Ono; Y. Miura; H. Hidaka;

Y. Tanaka; J. Takada; M. Watanabe; A. Shibuya

Background/Aims:

To elucidate the incidence of future hepatitis activation and

hepatocarcinogenesis in HBeAg-negative HBV carriers with persistently normal

alanine aminotransferase (PNALT), long-term observation was performed in a

prospective cohort.

Methods:

Ninety-nine consecutive untreated HBeAg-negative carriers with PNALT (40IU/L)

were prospectively included in the study. The physical examinations, laboratory

tests, and abdominal ultrasound sonography were performed every 6 months after

the enrollment. The incidence of hepatitis activation (ALT levels of more than

1.5x upper limit of normal) and hepatocarcinogenesis were examined. In addition,

we statistically investigated the contributed factors for hepatitis activation

and hepatocarcinogenesis among baseline clinical and virological features at the

enrollment. ALT level was classified into two groups of low-normal ALT (30IU/L)

and high-normal ALT (30-40IU/L).

Results:

The mean follow-up period was 65.3±36.8 months. Thirteen carriers (13%) revealed

hepatitis activation, and hepatocarcinogenesis was observed in 4 (3.7%). The

cumulative rate of hepatitis activation was 10.5% and 14.9% at 2 and 5 years,

while the cumulative rate of hepatocarcinogenesis was 2.9% and 12.3% at 5 and 8

years. In statistical analyses for future hepatitis activation, the univariate

analyses revealed high-normal ALT and serum HBV DNA level 105 (copies/ml), and

high-normal ALT was an independent contributed factor in a model [odds

ratio, 13.45; 95% confidence interval, 4.34-41.64, P50 years), high-normal ALT,

the incidence of hepatitis activation, and serum HBV DNA level 105 (copies/ml)

(P = 0.0045, 0.0017,